-
Product Insights
Occlusive Arterial Disease (OAD) - Drugs In Development, 2024
Empower your strategies with our Occlusive Arterial Disease (OAD) – Drugs In Development, 2024 report and make more profitable business decisions. Occlusive arterial disease (OAD), also known as peripheral arterial disease (PAD) or peripheral vascular disease (PVD), is characterized by the narrowing or blockage of arteries in the extremities, particularly the legs. This occurs due to atherosclerosis, a buildup of plaque made up of cholesterol, fats, calcium, and other substances within the arterial walls. Individuals with OAD may experience symptoms such...
-
Product Insights
Peripheral Artery Occlusive Disease (PAOD) - Drugs In Development, 2024
Empower your strategies with our Peripheral Artery Occlusive Disease (PAOD) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral artery occlusive disease (PAOD), also known as peripheral arterial disease (PAD), refers to a condition characterized by the narrowing or blockage of the arteries outside the heart, predominantly affecting the arteries in the legs. This narrowing occurs due to atherosclerosis, the buildup of plaque within the arterial walls, restricting blood flow to the limbs. Individuals with PAOD may...
-
Product Insights
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drugs In Development, 2024
Empower your strategies with our Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral arterial disease (PAD) and peripheral vascular disease (PVD) refer to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh, or calf muscles after activity, such as walking or climbing stairs (intermittent claudication); leg numbness or weakness; coldness in lower leg or foot, especially...
-
Product Insights
Diastolic Heart Failure - Drugs In Development, 2024
Empower your strategies with our Diastolic Heart Failure (HFpEF) – Drugs In Development, 2024 report and make more profitable business decisions. Diastolic heart failure, also known as heart failure with preserved ejection fraction, is a condition in which the heart's main pumping chamber becomes stiff and unable to fill properly. One of the two types of left-sided heart failure is diastolic heart failure. Main causes include high blood pressure, diabetes, coronary artery disease, and obesity. Untreated diastolic heart failure has the...
-
Product Insights
Thromboembolism - Drugs In Development, 2024
Empower your strategies with our Thromboembolism – Drugs In Development, 2024 report and make more profitable business decisions. A thromboembolism occurs when a blood clot (thrombus) break and travels in the bloodstream. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy, and surgery. The Thromboembolism drugs in development market research report provide comprehensive information...
-
Product Insights
Atrial Fibrillation - Drugs In Development, 2024
Empower your strategies with our Atrial Fibrillation – Drugs In Development, 2024 report and make more profitable business decisions. Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery. The Atrial Fibrillation drugs in development market research...
-
Product Insights
Hypertrophic Cardiomyopathy - Drugs In Development, 2024
Empower your strategies with our Hypertrophic Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions. Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise; sensation of rapid, fluttering or pounding heartbeats; and heart murmur. Hypertrophic cardiomyopathy usually is inherited. Treatment includes beta blockers, calcium channel blockers, and blood thinners. The...
-
Product Insights
Dilated Cardiomyopathy - Drugs In Development, 2024
Empower your strategies with our Dilated Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions. Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include fatigue and weakness, shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention, and swelling (edema) in legs, ankles, and...
-
Product Insights
Venous Thromboembolism - Drugs In Development, 2024
Empower your strategies with our Venous Thromboembolism – Drugs In Development, 2024 report and make more profitable business decisions. Venous thromboembolism (VTE) is a condition that occurs when a blood clot forms in a vein and blocks the blood flow. VTE can affect the deep veins of the legs or arms (deep vein thrombosis, or DVT) or the lungs (pulmonary embolism, or PE). VTE can cause serious complications such as tissue damage, organ failure, or death. VTE can be provoked by...
-
Product Insights
Critical Limb Ischemia - Drugs In Development, 2024
Empower your strategies with our Critical Limb Ischemia – Drugs In Development, 2024 report and make more profitable business decisions. Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet, and hands. Symptoms include pain or numbness in feet or toes, sores, and skin infections that do not heal. Treatment goals for CLI include reducing the number...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.